Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...

ORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial ...

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...

Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...

Following a low-carb diet may potentially help patients manage disease more effectively and reduce medication use. Study: Effects of a Carbohydrate-Restricted Diet on β-Cell Response in Adults With ...

Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference ...

The old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with type 1 diabetes, new research suggests. Results from the study were published ...

Please provide your email address to receive an email when new articles are posted on . Greater weight loss at 1 year with tirzepatide improved the odds for sustaining an HbA1c of 6.5% or less at 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A restricted ...